ALSO NOTED: UK officials give limited OK to Sativex; Lipitor fails to beat Zocor in head-to-head trial; Celsion to focus on dru

> Shares of the UK's GW Pharmaceuticals surged after UK officials indicated that its cannabis-based painkiller could be imported from Canada for certain uses. Earlier this year British regulators said they needed more data from GW before they could make a final decision on Sativex. Report

> A head-to-head trial of Pfizer's Lipitor versus Zocor failed to demonstrate that Lipitor was any better than Zocor in preventing heart attacks and deaths from heart disease. Report

> Maryland's Celsion is shifting out of the medical device field in order to focus on drug development work. A pending deal with Boston Scientific would fund the company through 2008, leaving the biotech enough resources to push a new drug down the pipeline. Article

> Researchers have identified gene variants that limit the effectiveness of statins in lowering bad cholesterol. Article

> Duke University Medical Center stands to gain $8 million to $10 million per year in royalties from an FDA approval of Genzyme's Myozyme for Pompe disease, which could come by year's end. Report

> South San Francisco-based Cell Genesys has announced positive Phase II data for its pancreatic cancer vaccine. Release

> Roche has rejected a possible link between Tamiflu and the recent suicides of two Japanese youths, saying there is no established link between the drug and abnormal behavior. Report

> Botox-maker Allergan has bid $3.2 billion for Inamed, which makes breast implants. Report

> The FDA wants a US court to reject a lawsuit from Novartis claiming undue regulatory delays in approving its generic human growth hormone. Report

And Finally… Seven Israeli biotech companies are journeying to investment capital-rich California this month to woo stem cell investors. Article